24日，美国国家安全顾问罗伯特·奥布莱恩（RobertO'Brien）在接受美国哥伦比亚广播公司（CBS）专访时，再度抹黑中国，称中国正在“窃取”美国疫苗相关研究成果。
当主持人问道，如果中国先研制出疫苗会怎样，罗伯特·奥布莱恩称，美国会先研制出疫苗，然后称：
It's been reported, that the Chinese have been engaged inespionage to try and find the research and the technologies thatwe're working on both for a vaccine and a therapy.
有报道说，中国在从事间谍活动，想盗取我们有关疫苗和治疗方法的研究和技术成果。
25日晚，外交部发言人华春莹转发相关报道，犀利回应道：
Interesting to hear some US official talking about the storyof vaccine. Is this the normal logic that if anyone has somethingbetter than mine, then it must be stolen from me? Remember, Chinahas 5000 years of history while the US has less than 250.
听一些美国官员谈论疫苗的故事，真是有意思。如果别人的东西比我更好，那一定是从我这里偷走的，这是正常的逻辑吗？记住，中国有5000年的历史，而美国的历史不到250年。”
针对奥布莱恩的抹黑言论，在25日的外交部例行记者会上，发言人赵立坚也作出回应。他强调美方的说法毫无根据。事实上，中方在研发新冠病毒疫苗方面取得了重大进展。
美方的说法毫无根据。事实上，中方在研发新冠病毒疫苗方面取得了重大进展。中国支持各国就新冠肺炎疫情加强信息分享，交流防控有益经验和做法，开展疫苗药物研发等领域国际合作。
The US allegations are groundless. In fact, China has madesignificant progress in developing a novel coronavirus vaccine.China supports further information-sharing on COVID-19 and exchangeof useful experience and practices between countries, as well asinternational cooperation in vaccine and drug research anddevelopment.
我想强调的是，新冠病毒疫苗研发不是中美之争，而是人类与病毒之争。哪个国家率先完成疫苗研发并投入使用都是对人类抗击疫情的积极贡献。人类正在同病毒赛跑，每天都有鲜活的生命被病毒无情夺走。疫苗是战胜病毒的关键。我们期待疫苗研发领域有更多的捷报频传。我们也期待继续同国际社会一道，为推进疫苗研发等全球抗疫合作添砖加瓦，共同打造人类卫生健康共同体。
I would like to underline that COVID-19 vaccine development isnot a race between China and the US, but a race between mankind andthe virus. No matter which country is the first to develop anddeploy a vaccine, it will be a great contribution to all mankind inthis fight. Mankind is racing against the virus, which claims livesruthlessly every day. As the vaccine is the key to defeating thevirus, we hope to hear more good news in this regard. We also standready to work with the international community to contribute ourshare to the concerted global response to COVID-19 including invaccine R&D and to forge a global community of health forall.
据了解，截至目前全球共有100多个科研团队、按多个技术路线全力攻关新冠疫苗。据科技部社会发展科技司司长吴远彬介绍，目前全球开展临床试验的疫苗总共有10个，中国有5款疫苗进入临床试验，其中包括陈薇院士团队研发的腺病毒载体疫苗，和4个灭活疫苗。
陈薇院士团队的腺病毒载体疫苗于3月底完成了一期临床试验受试者接种，并于4月12日启动了二期临床试验。
陈薇院士团队还发布了全球首个新冠病毒疫苗的人体试验结果。5月22日晚21时许，国际学术期刊《柳叶刀》（TheLancet）发布陈薇院士新冠疫苗I期临床试验结果。研究表明，这是第一种进入第一阶段临床试验的COVID-19疫苗，它具有良好的安全性和耐受性，并且能够诱导快速的免疫反应。
China's COVID-19 vaccine trial, the first such vaccine toreach phase 1 clinical trial, has been found to be safe,well-tolerated, and able to generate an immune response againstSARS-COV-2 in humans, according to a study published online on May22 by medical journal The Lancet.
《柳叶刀》主编理查德·霍顿通过社交媒体分享了这一研究成果，并称：
“These results represent an important milestone.”
“这些结果代表着重要的里程碑。”
来源：CBS News 外交部官网
声明：转载此文是出于传递更多信息之目的。若有来源标注错误或侵犯了您的合法权益，请作者持权属证明与本网联系，我们将及时更正、删除，谢谢。